• SHOP
    • COMBOS
    • TESTIMONIALS
    • CART
    • INGREDIENTS
      • 2-DEOXY-D-GLUCOSE (2DG)
      • ACACIA CYANOPHYLLA FLOWER
      • ACORI GRAMINEI RHIZOMA
      • AEGLE MARMELOS CORREA
      • AGARICUS BLAZEI
      • AGED GARLIC EXTRACT
      • AFRAMOMUM MELEGUETA
      • ALOE ARBORESCENS
      • ALBIZIA
      • ALPINIA OFFICINARUM
      • ALTERNANTHERA SESSILIS
      • AMERICAN GINSENG
      • AMYGDALIN
      • ANACYCLUS PYRETHRUM
      • ANGELICA ARCHANGELICA
      • ANGELICA SINENSIS
      • ANTRODIA
      • APIGENIN
      • ARTICHOKE LEAF
      • ARTOCARPIN
      • AJUGA TURKESTANICA
      • ASHWAGANDHA
      • ASPALATHIN
      • ASTRAGALUS COMPLANATUS
      • AVENA SATIVA
      • BACOPA MONNIERI
      • BAVACHIN
      • BEE POLLEN
      • BETULINIC ACID
      • BOSWELLIC ACID
      • BREVILIN A
      • CAMPESTEROL
      • CAPSAICIN
      • CARCININE
      • CASTICIN
      • CHRYSIN
      • CIANIDANOL
      • CINNAMOMUM ZEYLANICUM
      • CITRULLUS COLOCYNTHIS
      • CITRUS RETICULATA PEEL
      • CODONOPSIS
      • CONJUGATED LINOLEIC ACID
      • COSTUNOLIDE
      • CYANIDIN
      • CUCURBITACIN D
      • DAIDZEIN
      • DECURSIN
      • DELPHINIDIN
      • DIGITALIS PURPREA (DIGOXIN)
      • DIOSMIN
      • ELLAGIC ACID
      • EMBELIN
      • ERIODICTYOL
      • GALLIC ACID
      • GLYCITEIN
      • GLYCYRRHIZIN
      • HYPERFORIN
      • ICARIIN
      • ISORHAMNETIN
      • ISOORIENTIN
      • ISOVITEXIN
      • JACEOSIDIN
      • KAEMPFEROL
      • KIGELIA AFRICANA
      • KURARINONE
      • LEMON BALM
      • LICORICIDIN
      • LIPOIC ACID
      • LUPEOL
      • MAGNOLOL
      • MULBERRY LEAF
      • NARINGENIN
      • NOBILETIN
      • OLEACEIN
      • OLEANOLIC ACID
      • OLIVE OIL
      • ORIDONIN
      • PARTHENOLIDE
      • PHLOROGLUCINOL
      • PHLORIZIN
      • PICEATANNOL
      • PRISTIMERIN
      • PROANTHOCYANIDINS
      • PROCYANIDIN B3
      • PSEUDOLARIC ACID B
      • PTEROSTILBENE
      • RUTIN
      • SOLIDAGO VIRGAUREA
      • TANGERETIN
      • TARAXASTEROL
      • TRICHOSTATIN A
      • WEDELOLACTONE
      • WOGONIN
      • YERBA MATE
    • ABOUT
    • SCIENTIFIC STUDIES
      • ADAPTOGENS
      • ADIPOCYTE APOPTOSIS (KILLING FAT CELLS)
      • ADDICTION AND THE BRAIN
      • ADDICTION & STRESS
      • ADDICTION WITHDRAWAL
      • ADIPOCYTE DEDIFFERENTIATION (THE REVERSAL OF FAT FORMATION)
      • ADIPOCYTE DIFFERENTIATION
      • ALLERGIES & CYTOKINES
      • ALDOSTERONE & OBESITY/HYPERTENSION
      • ALZHEIMER’S, DEMENTIA, PARKINSON’S
      • ANTI-ACNE EFFECT OF FLAVONOIDS AND POLYPHENOLS
      • ADVANCED GLYCATION END PRODUCTS (AGES)
      • ADDICTION TREATMENT
      • AMPK
      • ANTI AGING
      • ANTIAGING EFFECTS OF COFFEE
      • ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-APOPTOTIC PATHWAYS
      • ANTI ATHEROGENIC
      • ANTI-CANCER EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI CARIOGENIC (Protecting From Tooth Decay)
      • ANTI COVID-19 EFFECTS OF MEDICINAL PLANTS, FLAVONOIDS & POLYPHENOLS
      • ANTI GLYCATIVE
      • ANTI GLYCATION AGENTS
      • ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-VIRAL EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI WRINKLE AGENTS
      • APOPTOSIS
      • APOPTOSIS IN 3T3-L1
      • AUTOPHAGY
      • BCL-2
      • BCL-W
      • BCL-XL
      • BDNF
      • BECLIN-1 & AUTOPHAGY
      • BH3 MIMETICS
      • BIM aka BCL2L11
      • BMI-1
      • BRASSINOSTEROIDS
      • CALORIE RESTRICTION
      • CALORIE RESTRICTION & LIFESPAN EXTENSION
      • CARBAMYLATION
      • CARBONYL SCAVENGER
      • CARBONYL STRESS
      • CARDIOPROTECTIVE AGENTS
      • CARDIAC GLYCOSIDES
      • CATALASE
      • CELL CYCLE ARREST
      • CENTENARIANS
      • CHOLESTEROL EFFLUX
      • COGNITIVE ENHANCEMENT
      • COLD SHOCK PROTEINS
      • COLD-INDUCIBLE RNA-BINDING PROTEIN (CIRBP) & DNA REPAIR
      • CONDITIONED PLACE PREFERENCE
      • CORTICOTROPIN RELEASING FACTOR
      • CRYOTHERAPY
      • CRYOLIPOLYSIS: FREEZING FAT TO DEATH
      • CYP2E1
      • CYTOKINES IN PAIN, INFLAMMATION & AGING
      • DAF-16
      • DIABETES & CANCER
      • DIHYDROTESTOSTERONE (DHT)
      • DNA METHYLATION & AGING
      • DNA REPAIR
      • DNA REPAIR VIA FLAVONOIDS & POLYPHENOLS
      • ADDICTION & DOPAMINE
      • DRY FASTING AND FLUID RESTRICTION FASTING
      • DYNORPHIN
      • ELLAGITANNINS
      • ENLARGED HEART AND CARDIOMEGALY
      • EPIGENETIC MODIFIERS
      • EPINEPHRINE
      • ERGOGENIC AGENTS (INCREASE ATHLETIC PERFORMANCE)
      • EXCITOXICITY & THE BRAIN
      • EXTRACELLULAR MATRIX STIFFENING (10TH HALLMARK OF AGING)
      • EXTENDS LIFESPAN
      • EXTINCTION TRAINING
      • FASTING BRAIN
      • FASTING CANCER
      • FASTING & CANCER
      • FASTING MIMICKING DIET
      • FEAR EXTINCTION
      • FGF21
      • FLAVONES
      • GABA (γ-AMINOBUTYRIC ACID)
      • GALLOTANNINS
      • GLUCONEOGENESIS
      • GLUTAMATE & BRAIN
      • GLYCATION
      • KLOTHO
      • FASTING, CALORIE RESTRICTION & EXTENDING LIFESPAN
      • FOXO3
      • FOXO4
      • HALLMARKS OF AGING
      • HEPATOPROTECTIVE AGENTS (KEEPING LIVER HEALTHY)
      • HMGB1
      • HORMESIS
      • HPA AXIS
      • HSP70, THE ANTI-AGING PROTEIN
      • HSP90 INHIBITORS
      • HYPERGLYCEMIA
      • HYPERINSULINEMIA
      • HYPOACTIVE SEXUAL DESIRE (WHY PEOPLE HAVE ZERO SEX DRIVE)
      • HYPOCRETIN OREXIN
      • IKK
      • IL-6/STAT3
      • IRISIN
      • ISOFLAVONES
      • IMMUNOSENESCENCE
      • INCREASE PROTEIN SYNTHESIS
      • INFECTOBESITY
      • INFLAMMATION & ANXIETY
      • INFLAMMATION & CANCER
      • INFLAMMATION & DEPRESSION
      • INFLAMMATION & OBESITY
      • INFLAMMAGING
      • INHIBITION OF RENAL GLUCOSE REABSORPTION
      • INSULIN & AGING
      • INSULIN & CANCER: HOW INSULIN LITERALLY PROTECTS CANCER CELLS FROM BEING KILLED
      • INSULIN & MTOR
      • INSULIN & OBESITY
      • INTERMITTENT FASTING
      • JAK INHIBITION ALLEVIATES SASP
      • JNK ACTIVATION PREVENTS PREMATURE SENESCENCE
      • KETONE BODIES
      • KETOGENIC DIET
      • LEYDIG CELL STEROIDOGENESIS
      • LIFESPAN EXTENSION
      • LIPOLYTIC AGENTS
      • LIPID DROPLETS
      • LIPOLYSIS (THE DECOMPOSITION OF BODY FAT)
      • LOWERING CHOLESTEROL THRU FASTING, DIET & MEDICINAL PLANTS
      • MATRIX METALLOPROTEINASES (MMPs)
      • MCL-1
      • MDM2 INHIBITION AS SASP INHIBITOR
      • MEDITERRANEAN DIET
      • MENAQUINONE 4
      • METABOLIC REPROGRAMMING
      • METABOLIC SYNDROME EXTRACT
      • METHIONINE RESTRICTION
      • MITOCHONDRIAL UNCOUPLING
      • MONKEYPOX
      • MSG (MONOSOSODIUM GLUTAMATE)
      • MUSCLE FORCE PRODUCTION
      • MUSCLE ATROPHY (PREVENTING)
      • MYOGENESIS
      • MYOSTATIN INHIBITION
      • MYOSTATIN INHIBITION PRESERVES MUSCLE
      • mTORC2
      • mTOR: THE RAPID AGING PATHWAY
      • NATURAL ANTICOAGULANTS
      • NATURAL AROMATASE INHIBITORS
      • NEUROGENESIS (GROWING NEW BRAIN CELLS)
      • NEUROCHEMISTRY OF ADDICTION
      • NEUROPLASTICITY
      • NEUROINFLAMMATION
      • NEUROPROTECTIVE AGENTS
      • NMDA & ANXIETY & DEPRESSION
      • NMDA RECEPTOR AND FEAR
      • NON-OPIOID ANALGESICS (PLANT BASED)
      • NOOTROPICS
      • NORADRENERGIC
      • NOREPINEPHRINE
      • NRF2: MASTER REGULATOR OF THE AGING PROCESS
      • NF-KB
      • ONCOGENE ACTIVATION INDUCED SENESCENCE
      • OVERNUTRITION
      • OXIDATIVE STRESS & AGING
      • P16INK4A
      • P38MAPK
      • P53: TUMOR SUPRESSOR
      • PERIODONTITIS
      • PHYTOCHEMICALS
      • PHYTOSTEROLS
      • PHYTOSTANOLS
      • PHYTOECDYSTEROIDS
      • PROANTHOCYANIDINS
      • PROTEIN CARBONYLATION
      • POLYAMINES & THEIR EFFECT ON BRAIN (NMDA, DEPRESSION, SUICIDE RISK)
      • PPARY2
      • PREMATURE SENESCENCE
      • PREVENTING SKIN AGING
      • PUFAS
      • PURGATIVES
      • RAPAMYCIN (MTOR INHIBITION)
      • RECEPTOR “Κ OPIOID”
      • RED WINE
      • RENAL (KIDNEY) PROTECTIVE AGENTS
      • REMINERALIZATION OF TEETH
      • REPAIR OF DNA BREAKS “DOUBLE STRAND”
      • RESTORE INSULIN SENSITIVITY
      • SASP & ADIPOSE TISSUE
      • SENESCENT CELLS, SASP & SENOLYTICS
      • SENESCENCE-BETA-GALACTOSIDASE (SA-β-gal or SABG)
      • SGLT2 INHIBITORS
      • SGLT2 INHIBITION FOR LIFESPAN EXTENSION
      • SHBG
      • SIRT1
      • SKELETAL MUSCLE HYPERTROPHY (THE SCIENCE OF BUILDING MUSCLE)
      • SKIN ELASTICITY
      • SKIN PHOTOAGING (Preventing & Repairing)
      • SLEEP DEPRIVATION AS THERAPY FOR DEPRESSION
      • SIRT1 & LONGEVITY
      • SMALLPOX
      • SUGAR & AGING
      • STAR PROTEIN
      • STAT3
      • STEM CELL EXHAUSTION
      • STEM CELL REGENERATION
      • STEM CELL THERAPY
      • STIMULATED LIPOLYSYS
      • STEROIDOGENESIS (THE PRODUCTION OF HORMONES IN BODY)
      • STREPTOCOCCUS MUTANS (MAIN BACTERIA BEHIND TOOTH DECAY)
      • STRESS & AGING
      • STRESS & THE BRAIN
      • TELOMERE SHORTENING & PREMATURE AGING
      • TIME RESTRICTED FEEDING
      • TRAUMATIC BRAIN INJURY (HEALING)
      • TRYPTOPHAN HYDROXYLASE 2
      • VISCERAL ADIPOSITY
    • HOME
    • CONTACT
    • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
    • The Ultimate Dry Fasting Resource
    0
    IMMUNOSENESCENCE
    March 8, 2021
    FEAR EXTINCTION
    March 11, 2021
    1. Aldosterone in obesity
    2. Resistant hypertension, obesity, sleep apnea, and Aldosterone: theory and therapy
    3. The role of Aldosterone in obesity-related hypertension
    4. Visceral obesity and insulin resistance are associated with plasma Aldosterone levels in women
    5. obesity, hypertension and Aldosterone: is leptin the link?
    6. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration
    7. Aldosterone production and signaling dysregulation in obesity
    8. Fibrosis and cardiac function in obesity: a randomised controlled trial of Aldosterone blockade
    9. Plasma Aldosterone, plasma lipoproteins, obesity and insulin resistance in humans
    10. The role of the renin-angiotensin-Aldosterone system in obesity-related renal diseases
    11. Adipocytes produce Aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus–associated obesity and vascular dysfunction
    12. Adipocytes, Aldosterone and obesity-related hypertension
    13. The link between the renin-angiotensin-Aldosterone system and renal injury in obesity and the metabolic syndrome
    14. Leptin-Aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity
    15. The renin–angiotensin–Aldosterone system as a link between obesity and coronavirus disease 2019 severity
    16. obesity, sleep apnea, Aldosterone, and hypertension
    17. Morbid obesity, hypertensive disease and the renin-angiotensin-Aldosterone axis
    18. Vasculometabolic and Inflammatory Effects of Aldosterone in obesity
    19. A critical review of the evidence supporting Aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension
    20. The regulation of Aldosterone secretion by leptin: implications in obesity-related cardiovascular disease
    21. The renin angiotensin Aldosterone system in obesity and hypertension: roles in the cardiorenal metabolic syndrome
    22. obesity-related heart failure with a preserved ejection fraction: the mechanistic rationale for combining inhibitors of Aldosterone, neprilysin, and sodium-glucose …
    23. The association of Aldosterone with obesity-related hypertension and the metabolic syndrome
    24. The link between adipose tissue renin-angiotensin-Aldosterone system signaling and obesity-associated hypertension
    25. The involvement of Aldosterone on vascular insulin resistance: implications in obesity and type 2 diabetes
    26. Interaction of Aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review
    27. Fat cells may be the obesity–hypertension link: human adipogenic factors stimulate Aldosterone secretion from adrenocortical cells
    28. obesity and cardiovascular disease: role of adipose tissue, inflammation, and the renin-angiotensin-Aldosterone system
    29. Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and Aldosterone levels in morbid obesity
    30. Role of mineralocorticoid receptor and renin–angiotensin–Aldosterone system in adipocyte dysfunction and obesity
    31. Aldosterone deficiency in mice burdens respiration and accentuates diet-induced hyperinsulinemia and obesity
    32. obesity-induced hypertension develops in young rats independently of the renin-angiotensin-Aldosterone system
    33. Differential effects of renin–angiotensin–Aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity …
    34. Role of renin-angiotensin-Aldosterone system in metabolic syndrome and obesity-related hypertension
    35. Relationship between obesity, hypertension, and Aldosterone production in postmenopausal African American women: a pilot study
    36. Response to ‘renal injury in extreme obesity: the important role of Aldosterone‘
    37. Increased Aldosterone: mechanism of hypertension in obesity
    38. Changes in serum Aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults
    39. Aldosterone is involved in the pathogenesis of obesity-related glomerulopathy through activation of Wnt/β-catenin signaling in podocytes
    40. Impact of obesity on the association of active renin and plasma Aldosterone concentrations, and Aldosterone-to-renin ratio with preeclampsia
    41. Reviving the use of Aldosterone inhibitors in treating hypertension in obesity
    42. Race, obesity, and the renin-angiotensin-Aldosterone system: treatment response in children with primary hypertension
    43. obesity and the renin–angiotensin–Aldosterone system
    44. PS 08-85 ASSOCIATION OF Aldosterone SYNTHASE (CYP11B2) GENE POLYMORPHISMS WITH obesity IN ESSENTIAL HYPERTENSIVE CHILDREN AND …
    45. Beneficial long-term effect of Aldosterone antagonist added to a traditional blockade of the renin–angiotensin–Aldosterone system among patients with obesity …
    46. Changes in Aldosterone and obesity-related cardiometabolic risk factors with a 1-year weight loss intervention in normotensive overweight and obese young …
    47. Insulin resistance and the renin-angiotensin-Aldosterone system in metabolic syndrome and obesity-related hypertension
    48. The renin, angiotensin, Aldosterone, and obesity connection
    49. The renin-angiotensin-Aldosterone system (RAAS) and its relation with calcium homeostasis in male obesity
    50. The Relationship between obesity, insulin resistance and Aldosterone levels
    51. Emerging role of Aldosterone in mediating the vicious cycle of obesity, insulin resistance and metabolic syndrome
    52. Distribution of genotypes and alleles of the Aldosterone-synthase gene in patients with abdominal obesity
    53. Targeting the Renin-Angiotensin-Aldosterone System in obesity
    54. Altered circadian plasma cortisol and Aldosterone group rhythms in Cushing’s syndrome versus obesity and health.
    55. Characteristics of the Renin-Angiotensin-Aldosterone System in Carriers of Polymorphic Variants of the VDR Gene With Arterial hypertension and obesity
    56. obesity-stimulated Aldosterone release is not related to an S1P-dependent mechanism
    57. ARTERIAL STIFFNESS, Aldosterone, CRP AND DIASTOLIC DYSFUNCTION IN PATIENTS WITH hypertension, obesity AND ATRIAL FIBRILLATION
    58. RENIN-ANGIOTENSIN-Aldosterone SYSTEM IN PATIENTS WITH ABDOMINAL obesity AND ARTERIAL hypertension
    59. Changes in excretion of Aldosterone in urine during absolute starvation in essential obesity.
    60. The Renin-Angiotensin-Aldosterone System as a Link Between obesity and Coronavirus Disease 2019 Severity
    61. Effect of Aldosterone receptor antagonist on obesity-related glomerulonephropathy
    62. Aldosterone Production and Signaling Dysregulation in obesity
    63. Adipocyte-derived Aldosterone And Cortisol Are Nox1/4 Dependent: Implications In obesity-associated Vascular Dysfunction.
    64. … efficacy and safety of dual blockage of the renin-angiotensin-Aldosterone system in patients with type 2 diabetes, hypertension and obesity without renal dysfunction
    65. Role of Aldosterone in obesity-induced endothelial dysfunction
    66. Aldosterone synthase gene polymorphism in alimentary obesity, metabolic syndrome components, some secondary forms of arterial hypertension, pathology of the …
    67. RELATIONSHIP BETWEEN obesity AND PLASMA Aldosterone IN ESSENTIAL hypertension: INFLUENCE OF GENDER: PP. 34.372
    68. Possible Interactions Among Fatty Acids, Other Lipids, and Aldosterone in the hypertension of obesity
    69. Influence of Race and obesity on the Renin-Angiotensin-Aldosterone System in Adolescents Born Preterm
    70. Does Renin‐Angiotensin‐Aldosterone System Inhibition Impact obesity as a Co–Risk Factor?
    71. P658Left ventricular function improvement by Aldosterone blockade in obesity: contribution of beneficial changes in collagen turnover
    72. BAS/BSCR35 Effects of Aldosterone and obesity on the anticontractile properties of perivascular adipose tissue in rat aortic rings
    73. Abstract MP009: Changes in Aldosterone are Associated With Changes in obesity-Related Factors in Normotensive Overweight/Obese Young Adults Undergoing …
    74. RENIN-ANGIOTENSIN-Aldosterone-SYSTEM IN PATIENTS WITH ABDOMINAL obesity AND hypertension: PP. 26.334
    75. The relationship between renin-Aldosterone system and obesity in non-insulin dependent diabetes mellitus (NIDDM).
    76. Role of the adipose-tissue renin-angiotensin-Aldosterone system in obesity and obesity-associated hypertension.
    77. obesity, adipocytes, and the renin-angiotensin-Aldosterone axis.
    78. … of Aldosterone, Plasma Renin Activity (PRA) and Superoxide Dismutase (SOD) with Inflammation and Insulin Resistance in Adult Men with Central obesity
    79. Effect of obesity on Activation of the Renin Angiotensin-Aldosterone system in Patients with Moderate to Advanced Heart Failure
    80. Differential aspects of the dynamics of the renin-angiotensin-Aldosterone system in obesity with and without hypertension and in essential arterial hypertension
    81. … receptor agonists and antagonists of Aldosterone on the performance of daily blood pressure monitoring in patients with hypertension and concomitant obesity
    82. Hyperinsulinemia Leads the Elevation of Plasma Aldosterone Concentration Independently with obesity, Dyslipidemia, and Insulin Resistance in Patients with Type 2 …
    83. Function of the adrenal cortex in obesity. 6. Aldosterone secretion and excretion of its metabolites during some dynamic tests.
    84. Abstract A39: Gene-environment interactions between SNPs in the renin-angiotensin-Aldosterone system and hypertension, obesity, and blood pressure-related …
    85. Function of the adrenal cortex in obesity. 5. Daily secretion of Aldosterone.
    86. … : C-344T Aldosterone-SYNTHASE GENE POLYMORPHISM AND RENIN-ANGIOTENSIN-Aldosterone SYSTEM IN PATIENTS WITH ABDOMINAL obesity
    87. … growth factor-23—klotho—vitamin D 3 axis and the renin—angiotensin—Aldosterone axis in the development and progression of obesity-related kidney disease
    88. PS 04-15 MICE LACKING Aldosterone SYNTHASE OR TREATED WITH EPLERENONE ARE RESISTANT TO DIET-INDUCED obesity
    89. Role of NADPH oxidase (Nox) 1/4 in adipocyte-derived Aldosterone production and in inflammation and fibrosis in obesity
    90. 6.1 hypertension Associated with obesity or Overweight: a Role for Aldosterone?
    91. The renin–angiotensin–Aldosterone system, glucose metabolism and diabetes
    92. Plasma Aldosterone concentration in the patient with diabetes mellitus Rapid Communication
    93. Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases
    94. Local renal Aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor
    95. Aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease
    96. Renin‐angiotensin‐Aldosterone system in diabetes and hypertension
    97. Diabetes mellitus, the renin-angiotensin-Aldosterone system, and the heart
    98. The role of the renin-angiotensin-Aldosterone system in diabetes and its vascular complications
    99. Selective Aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes
    100. Renin‐angiotensin‐Aldosterone system, glucose metabolism and incident type 2 diabetes mellitus: MESA
    101. … role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, Aldosterone and catecholamines in type 1 (insulin-dependent) diabetes …
    102. Blockade of the renin–angiotensin–Aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes
    103. Sodium, renin, Aldosterone, catecholamines, and blood pressure in diabetes mellitus
    104. Diabetes and reninangiotensin-Aldosterone system: implications for COVID-19 patients with diabetes treatment management
    105. Evidence for renoprotection by blockade of the renin–angiotensin–Aldosterone system in hypertension and diabetes
    106. Aldosterone and myocardial extracellular matrix expansion in type 2 diabetes mellitus
    107. The crosstalk between insulin and renin-angiotensin-Aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention
    108. Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–Aldosterone system in type 2 diabetes: a prospective study using …
    109. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus
    110. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic …
    111. Aldosterone, renin, and diabetes mellitus in African Americans: the Jackson Heart Study
    112. A systematic review of the role of renin angiotensin Aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy
    113. Increased Aldosterone levels in a model of type 2 diabetes mellitus
    114. Aldosterone increases urine production and decreases apical AQP2 expression in rats with diabetes insipidus
    115. Renin-angiotensin-Aldosterone system activation in long-standing type 1 diabetes
    116. Impact of the renin-angiotensin-Aldosterone-system on cardiovascular and renal complications in diabetes mellitus
    117. The renin-angiotensin-Aldosterone system and the eye in diabetes
    118. Big renin and biosynthetic defect of Aldosterone in diabetes mellitus
    119. The state and responsiveness of the renin-angiotensin-Aldosterone system in patients with type II diabetes mellitus
    120. Aldosterone and type 2 diabetes mellitus
    121. Renin-angiotensin-Aldosterone system blockade is associated with higher risk of contrast-induced acute kidney injury in patients with diabetes
    122. Renin angiotensin Aldosterone system blockade and renal disease in patients with type 2 diabetes: an Asian perspective from the RENAAL study
    123. Blocking the renin-angiotensin-Aldosterone system to prevent diabetes mellitus
    124. Aldosterone responsiveness in patients with diabetes mellitus
    125. miR-196b-5p-enriched extracellular vesicles from tubular epithelial cells mediated Aldosterone-induced renal fibrosis in mice with diabetes
    126. Renin-angiotensin-Aldosterone system in diabetes mellitus.
    127. Effect of renin–angiotensin–Aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review …
    128. Diabetes impairs the vascular effects of Aldosterone mediated by G protein-coupled estrogen receptor activation
    129. The renin-angiotensin-Aldosterone system is suppressed in adults with type 1 diabetes
    130. Determinants and changes associated with Aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy
    131. Cardiac Aldosterone overexpression prevents harmful effects of diabetes in the mouse heart by preserving capillary density
    132. The role of renin–angiotensin–Aldosterone system‐based therapy in diabetes prevention and cardiovascular and renal protection
    133. The role of Aldosterone in cardiovascular disease in people with diabetes and hypertension: an update
    134. Aldosterone induces Vasoconstriction in Individuals with Type 2 Diabetes: Effect of Acute Antioxidant administration
    135. Renin–angiotensin–Aldosterone system genotypes and haplotypes affect the susceptibility to nephropathy in type 2 diabetes patients
    136. Higher screening Aldosterone to renin ratio in primary aldosteronism patients with diabetes mellitus
    137. Eplerenone reduces proteinuria in type II diabetes mellitus: implications for Aldosterone involvement in the pathogenesis of renal dysfunction
    138. The tissue renin-angiotensin-Aldosterone system in diabetes mellitus
    139. Impact of aliskiren treatment on urinary Aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy
    140. Genetic variant of the renin-angiotensin system and prevalence of type 2 diabetes mellitus: a modest but significant effect of Aldosterone synthase
    141. The study of renin–angiotensin–Aldosterone in experimental diabetes mellitus
    142. Renin-angiotensin-Aldosterone system, electrolyte homeostasis and blood pressure in alloxan diabetes.
    143. The role of the tissue renin-angiotensin-Aldosterone system in the development of metabolic syndrome, diabetes mellitus and itsvascular complications
    144. Serum potassium is a predictor of incident diabetes in African Americans with normal Aldosterone: the Jackson Heart Study
    145. Renin angiotensin Aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes
    146. Effect of renin-angiotensin-Aldosterone system inhibitors on all-cause mortality and major cardiovascular events in patients with diabetes: A meta-analysis focusing on …
    147. Renin angiotensin Aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study
    148. Responsiveness of plasma renin and Aldosterone in diabetes mellitus
    149. Glucose-induced hyperkalemia with normal Aldosterone levels: Studies in a patient with diabetes mellitus
    150. … between urinary sodium excretion and serum Aldosterone in patients with diabetes in the presence and absence of modifiers of the renin–angiotensin–Aldosterone …
    151. Low plasma Aldosterone despite normal plasma renin activity in uncomplicated type 1 diabetes mellitus: effects of RAAS stimulation
    152. Ongoing treatment with renin-angiotensin-Aldosterone-blocking agents does not predict normoalbuminuric renal impairment in a general type 2 diabetes population
    153. Associations between glycaemic control and activation of the renin-angiotensin-Aldosterone system in participants with type 2 diabetes mellitus and hypertension
    154. Individual variability in response to renin angiotensin Aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care …
    155. Endocrinological aspects of proteinuria and podocytopathy in diabetes: role of the Aldosterone/mineralocorticoid receptor system
    156. Decreases in renin and Aldosterone secretion in alloxan diabetes: an effect of insulin deficiency
    157. The renin‐Aldosterone axis in patients with diabetes insipidus
    158. Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems
    159. Aldosterone-mediated apical targeting of ENaC subunits is blunted in rats with streptozotocin-induced diabetes mellitus
    160. The potential benefits of Aldosterone antagonism in Type 2 diabetes mellitus
    161. Renin-angiotensin-Aldosterone system blockade in diabetes: role of direct renin inhibitors
    162. Mechanistic and clinical aspects of renin-angiotensin-Aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease
    163. Reduced plasma Aldosterone concentrations in randomly selected patients with insulin‐dependent diabetes mellitus
    164. Increased integrated concentration of norepinephrine, epinephrine, Aldosterone, and growth hormone in patients with uncontrolled juvenile diabetes mellitus
    165. Effect of sodium glucose co-transporter-2 inhibition on the Aldosterone/renin ratio in type 2 diabetes mellitus
    166. Changes of Aldosterone levels in patients with type 2 diabetes complicated by moderate to severe obstructive sleep apnea–hypopnea syndrome before and after …
    167. Effects of SGLT2 Inhibitors on Renin-Aldosterone System for One Month and Six Months in Type 2 Diabetes
    168. Renin–angiotensin–Aldosterone–blockade is associated with decreased use of antidepressant therapy in patients with type 1 diabetes and diabetic nephropathy
    169. … of the antihypertensive and antialbuminuric response to higher doses of renin–angiotensin–Aldosterone system blockade in albuminuric hypertensive type 2 diabetes …
    170. Effect of acute hyperglycaemia on plasma potassium and Aldosterone levels in type 2 (non-insulin-dependent) diabetes
    171. Atrial natriuretic peptide and renin-angiotensin-Aldosterone system in non-insulin-dependent diabetes mellitus.
    172. Dissociation of renin and Aldosterone during dehydration: studies in a case of diabetes insipidus and adipsia
    173. Responsiveness of plasma Aldosterone to angiotensin II in patients with diabetes mellitus
    174. Aldosterone responses to angiotensin II, adrenocorticotropin, and potassium in chronic experimental diabetes mellitus in rats
    175. RU28318, an Aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes
    176. Renin angiotensin-Aldosterone system (RAAS) blockers usage among type II diabetes mellitus patients—A Retrospective Study
    177. Add-on antihypertensive medications to angiotensin-Aldosterone system blockers in diabetes: a comparative effectiveness study
    178. Renin-Aldosterone responsiveness in uncomplicated juvenile-type diabetes mellitus
    179. Renin-Aldosterone axis in normoalbuminuric insulin-dependent diabetes mellitus patients with glomerular hyperfiltration
    180. … Renal Association clinical guidelines: hypertension management and renin-angiotensin-Aldosterone system blockade in patients with diabetes, nephropathy and/or …
    181. … of cilnidipine on sympathetic nerve activity and cardiorenal function in hypertensive patients with type 2 diabetes mellitus: association with BNP and Aldosterone …
    182. Blockade of the renin-angiotensin-Aldosterone system and renal protection in diabetes mellitus
    183. Renin‐Angiotensin‐Aldosterone System Blockers in Elderly Adults with Chronic Kidney Disease without Diabetes Mellitus or Proteinuria
    184. Altered relation of the renin-Aldosterone system and vasoactive peptides in type 2 diabetes: the KORA F4 study
    185. Renin-angiotensin-Aldosterone system antagonists and the prevention of type 2 diabetes mellitus
    186. Advanced glycation of high-density lipoprotein and the functionality of Aldosterone release in type 2 diabetes
    187. Renin angiotensin Aldosterone system altered in resistant hypertension in Sub-Saharan African diabetes patients without evidence of primary hyperaldosteronism
    188. Responsiveness of plasma 18-hydroxycorticosterone and Aldosterone to angiotensin II or corticotropin in nonazotemic diabetes mellitus
    189. Production of Aldosterone in male rats with inherited diabetes insipidus (Brattleboro strain)
    190. … –Aldosterone system before and during submaximal bicycle exercise in relation to circulatory catecholamines in patients with Type 1 (insulin-dependent) diabetes …
    191. THE RENIN‐Aldosterone SYSTEM IN NEPHROGENIC DIABETES INSIPIDUS AND THE INFLUENCE OF HYDROCHLOROTHIAZIDE AND INDOMETHACIN
    192. Recurrent hyperkalemic renal tubular acidosis and hyponatremia in diabetes mellitus due to Aldosterone resistance
    193. Renin-Angiotensin-Aldosterone system inhibition in prevention of diabetes mellitus.
    194. P153 Modulation of renin-angiotensin-Aldosterone system reverses adverse left atrial remodelling in type 2 diabetes
    195. Renoprotective effects of renin–angiotensin–Aldosterone system blockers in type 2 diabetes: demystifying multiple treatment comparisons in a network meta-analysis
    196. Relationships between renin, Aldosterone, blood pressure and renal function in hypertensive insulin-dependent diabetes mellitus
    197. Aldosterone responsiveness to an acute potassium load in diabetes mellitus and chronic renal insufficiency
    198. Diabetes Mellitus and Risks of Dual Blockade of the Renin-angiotensin-Aldosterone System
    199. Effects of amiloride on oral glucose loading, serum potassium, renin, and Aldosterone in diet‐controlled diabetes
    200. Glomerular hyperfiltration in insulin-dependent diabetes mellitus: no evidence for enhanced activity of the renin-angiotensin-Aldosterone system
    201. Renin–angiotensin–Aldosterone system blockade and urinary albumin excretion in community‐based patients with Type 2 diabetes: The Fremantle Diabetes Study
    202. Genetic polymorphism of renin-angiotensin-Aldosterone system in type 2 diabetes and in combination with arterial hypertension among Dagestan inhabitants
    203. The function of Aldosterone in patients with diabetes
    204. Renin-angiotensin-Aldosterone system in diabetes insipidus
    205. Diabetes insipidus after surgery of intracranial arterial aneurysms–with special reference to the human ADH and Aldosterone secretion (author’s transl)
    206. … angiotensin converting enzyme (ACE) insertion/deletion and Aldosterone synthase (CYP11B2)-344C/T polymorphisms in relation to type 2 diabetes mellitus risk in …
    207. The Role of Aldosterone in Diabetes-Related Vascular Disease: A New Therapeutic Target?
    208. Plasma renin and Aldosterone in youngsters with insulin-dependent diabetes mellitus
    209. The efficacy and safety of dual blockage of the renin-angiotensin-Aldosterone system in patients with type 2 diabetes, hypertension and obesity without renal …
    210. Azelnidipine Decreased Plasma Aldosterone andPlasminogen Activator Inhibitor Type 1 Levelsin the Hypertensive Patients with Type 2 Diabetes Mellitus―the Jikei …
    211. Relationship between Aldosterone and diabetes mellitus and its chronic complications
    212. Correlation Between Aldosterone and Gestational Diabetes Mellitus.
    213. Effects of Aldosterone, methylprednisolone and triiodothyronine on the response to water loading in the conscious hypothyroid rat with diabetes insipidus.
    214. Aldosterone excess: a rare non-nephrophathic cause of hypertension in type I diabetes.
    215. 538-P: Copeptin and Renin Angiotensin Aldosterone System (RAAS) Activation in Long-Standing Type 1 Diabetes (T1D)
    216. The potential benefits of Aldosterone antagonism in Type 2 diabetes mellitus
    217. Mineralocorticoid receptor and diabetes: in favour of other corticosteroids than Aldosterone
    218. Aldosterone prevents deleterious effects of diabetes in mouse hearts
    219. The effect of rosiglitazone combined with insulin on plasma Aldosterone in diabetes patients
    220. Aldosterone and Protein Disulfide Isomerase Activity in Diabetes
    221. Aldosterone Prevents Deleterious Effects of Diabetes in Mouse Hearts by a Proangiogenic Effect
    222. hypertension management and renin-angiotensin-Aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease
    223. … , May 15, 10: 00 AM-12.00 PM: Rationale for Aldosterone receptor blockade in the treatment of cardiovascular diseases*: Aldosterone receptor antagonists in diabetes …
    224. Pancreatic Renin‐Angiotensin‐Aldosterone System in the Cardiometabolic Syndrome and Type 2 Diabetes Mellitus
    225. … of acid-releasing renal function of rats in the dynamics of experimental diabetes mellitus with underlying pharmacological blockade of renin-angiotensin-Aldosterone …
    226. Cardiovascular Complications in Diabetes: Role of Aldosterone and Mineralocorticoid Receptors
    227. Acute Aldosterone Administration Increases Vascular Resistance in Patients with Type 2 Diabetes
    228. The Increase of Plasma Aldosterone Concentrations Were Correlated with Insulin Resistance in Patients with Type 2 Diabetes Mellitus.
    229. Aldosterone antagonism in type 2 diabetes mellitus—a new therapeutic approach to diabetic macrovascular disease?
    230. N‐Acetylcysteine Attenuates Aldosterone induced Vasoconstriction in Individuals with Type 2 Diabetes
    231. Relationship Between Circulating Aldosterone and Adipocytokines or Oxidative Stress in Patients With Type 2 Diabetes
    232. Renin Angiotensin Aldosterone System (RAAS) Activation and Diabetic Nephropathy (DN) Resistor Status in Longstanding Type 1 Diabetes
    233. … Usage of Renin-Angiotensin-Aldosterone System Blocking Agents on Incidence of Contrast-Induced Nephropathy in Patients with Diabetes Mellitus and Renal …
    234. Comparison of the morphological changes in the capillaries and the state of the renin-angiotensin-Aldosterone system in diabetes mellitus
    235. RENIN-ANGIOTENSIN-Aldosterone SYSTEM IN DIABETES MELLITUS
    236. H003 Cardiac Aldosterone overexpression prevents harmful effects of diabetes in mouse heart by preserving capillary density
    237. Correlation between insulin resistance and renin-angiotensin-Aldosterone system in newly diagnosed type 2 diabetes mellitus
    238. Plasma and Urinary Aldosterone Levels in Rats with Non-Insulin Dependent Diabetes Mellitus-Association with Myocardial Fibrosis
    239. The role of the renin-angiotensin-Aldosterone system blockade in preventing type 2 diabetes
    240. G Protein-coupled Estrogen Receptor Contributes To The Vascular Effects Of Aldosterone And Type Two Diabetes-associated Vascular Dysfunction
    241. Ednit effects on activity of renin-angiotensin-Aldosterone system and renal function in hypertensive subjects with diabetes mellitus
    242. Effects of atenolol add-on treatment on plasma renin activity (PRA) and Aldosterone escape in hypertensive patients with diabetes receiving valsartan
    243. Are renin angiotensin Aldosterone system gene polymorphisms risk factors for hypertension and diabetes? A literature review report from Malaysia
    244. … ADHERENCE TO RENIN-ANGIOTENSIN-Aldosterone-SYSTEM (RAAS) INHIBITORS AND RENAL FUNCTION AMONG PATIENTS WITH TYPE 2 DIABETES: A …
    245. Orthostatic hypotension in complicated diabetes mellitus: study of the renin-angiotensin-Aldosterone system (author’s transl)
    246. Diabetes mellitus type-II related hypertension and cardiovascular diseases: involvement of impaired regulatory renin-angiotensin-Aldosterone system
    247. Abstract P632: Nlrp3/inflammasome Activation Contributes To Aldosterone-induced Vascular Dysfunction In Type 2 Diabetes.
    248. … autonomous Aldosterone secretion in patients with type 2 Diabetes Mellitus and arterial hypertension. The effect of SGLT2 inhibitors on renin-angiotensin-Aldosterone …
    249. Effect of sodium depletion on the renin-angiotensin-Aldosterone system and prostaglandins in patients with insulin-dependent diabetes mellitus
    250. Impaired Sodium Excretion during Water Immersion in Diabetes Mellitus: Observations on the Renin-Aldosterone System
    251. Renin‐angiotensin‐Aldosterone system blockade ameliorates myocardial and ventricular function of rats with diabetes mellitus
    252. … Leads the Elevation of Plasma Aldosterone Concentration Independently with obesity, Dyslipidemia, and Insulin Resistance in Patients with Type 2 Diabetes Mellitus
    253. Renin-Angiotensin-Aldosterone System of Local Organizations and Chronic Complications of Type 2 Diabetes
    254. Aldosterone, Not Leptin, is Correlated With High Sympathetic Activity in Resistant hypertension With or Without Type 2 Diabetes
    255. … with angiotensin converting enzyme inhibitor and Aldosterone antagonist on insulin sensitivity and serum leptin concentration in patients with type 2 diabetes …
    256. … NITRIC OXIDE SYNTHASE, ANGIOTENSINOGEN AND Aldosterone SYNTHASE GENE POLYMORPHISMS IN TYPE 2 DIABETES MELLITUS AND THEIR …
    257. The kidney in diabetes mellitus: urinary transfer in excretion, hypertension, the Renin-Angiotensin-Aldosterone system, and the role of angiotensin converting enzyme …
    258. PP. 09.11: ASSOCIATION OF PLASMA Aldosterone CONCENTRATION WITH PREVALENCE OF DIABETES MELLITUS IN SUSPECTED PRIMARY …
    259. CMS and Type 2 Diabetes Mellitus: Bound Together by the Renin Angiotensin Aldosterone System
    260. … irbesartan, and perindopril plus irbesartan on blood pressure, renal hemodynamics, proteinuria, renin angiotesin-Aldosterone system, and TGF-B1, in type 2 diabetes …
    261. A Nox4 Inhibitor, GKT 137831, Decreases Aldosterone Synthesis, Adiposity and Vascular Contractility in a Murine Model of Diabetes.
    262. Effect of 5-month guanfacine treatment on the renin-angiotensin-Aldosterone system and some metabolic factors in patients with diabetes mellitus type II and …
    263. S-423 Plasma Aldosterone level and its metabolic implications in patients with type 2 diabetes
    264. … CILNIDIPINE ON SYMPATHETIC NERVOUS SYSTEM AND PLASMA Aldosterone CONCENTRATION IN HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES …
    265. … OF THE RENIN-ANGIOTENSIN SYSTEM AND PREVALENCE OF TYPE 2 DIABETES MELLITUS. A MODEST BUT SIGNIFICANT EFFECT OF Aldosterone …
    266. Aldosterone and arterial hypertension
    267. Mechanisms of hypertension: the expanding role of Aldosterone
    268. Serum Aldosterone and the incidence of hypertension in nonhypertensive persons
    269. Structural analysis and evaluation of the Aldosterone synthase gene in hypertension
    270. Genetic determination of plasma Aldosterone levels in essential hypertension
    271. Essential hypertension: renin and Aldosterone, heart attack and stroke
    272. Role of Aldosterone in left ventricular hypertrophy in hypertension
    273. hypertension: renin–angiotensin–Aldosterone system alterations
    274. Narrative review: the emerging clinical implications of the role of Aldosterone in the metabolic syndrome and resistant hypertension
    275. Aldosterone-receptor antagonism in hypertension
    276. Global-and renal-specific sympathoinhibition in Aldosterone hypertension
    277. Aldosterone, hypertension, and cardiovascular disease: an endless story
    278. Saline suppression of plasma Aldosterone in hypertension
    279. Plasma Aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension
    280. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension
    281. The renin-angiotensin-Aldosterone system: a specific target for hypertension management
    282. Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and Aldosterone profiles
    283. ICV infusion of corticosterone antagonizes ICV-Aldosterone hypertension
    284. hypertension, increased Aldosterone secretion and low plasma renin activity relieved by dexamethasone
    285. Aldosterone Excretion Rate and Blood Pressure in Essential hypertension Are Related to Polymorphic Differences in the Aldosterone Synthase Gene CYP11B2
    286. Resistant hypertension, obstructive sleep apnoea and Aldosterone
    287. Aldosterone and the risk of hypertension
    288. Somatic mutations in ATP1A1 and ATP2B3 lead to Aldosterone-producing adenomas and secondary hypertension
    289. Aldosterone-to-renin ratio, arterial stiffness, and the response to Aldosterone antagonism in essential hypertension
    290. Intracerebroventricular infusion of Aldosterone induces hypertension in rats
    291. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome
    292. Aldosterone and the vasculature: mechanisms mediating resistant hypertension
    293. Association between increased plasma levels of Aldosterone and decreased systemic arterial compliance in subjects with essential hypertension
    294. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea
    295. Aldosterone, inflammation, immune system, and hypertension
    296. Characterization of resistant hypertension: association between resistant hypertension, Aldosterone, and persistent intravascular volume expansion
    297. Severity of obstructive sleep apnea is related to Aldosterone status in subjects with resistant hypertension
    298. Central interactions of Aldosterone and angiotensin II in Aldosterone-and angiotensin II-induced hypertension
    299. Eplerenone, a selective Aldosterone blocker, in mild-to-moderate hypertension
    300. A chimaeric llβ-hydroxylase/Aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension
    301. Influence of arterial blood pressure and Aldosterone on left ventricular hypertrophy in moderate essential hypertension
    302. Association of the C− 344T Aldosterone synthase gene variant with essential hypertension: a meta-analysis
    303. Increased cardiac types I and III collagen mRNAs in Aldosterone-salt hypertension.
    304. A new mutation, R563Q, of the beta subunit of the epithelial sodium channel associated with low-renin, low-Aldosterone hypertension
    305. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of Aldosterone synthase
    306. Arterial pressure, left ventricular mass, and Aldosterone in essential hypertension
    307. Vascular complications in patients with Aldosterone producing adenoma in Japan: comparative study with essential hypertension
    308. Effects of the selective Aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension
    309. Aldosterone is produced from ventricles in patients with essential hypertension
    310. Aldosterone antagonists in hypertension and heart failure.
    311. Aldosterone antagonist improves diastolic function in essential hypertension
    312. Molecular basis of salt sensitivity in human hypertension: evaluation of renin-angiotensin-Aldosterone system gene polymorphisms
    313. Aldosterone secretion and primary and malignant hypertension
    314. Experimental Aldosterone hypertension in the dog.
    315. Intracerebroventricular infusion of RU28318 blocks Aldosterone-salt hypertension
    316. Influence of antihypertensive medication on Aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism
    317. Variation at the Aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised Aldosterone-to-renin ratio
    318. Renin-Aldosterone Relationships in Pregnancy-Induced hypertension: An Alternative Viewpoint
    319. Molecular genetics of the renin-angiotensin-Aldosterone system in human hypertension.
    320. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, Aldosterone excess, and low plasma renin
    321. hypertension and severe hyperkalaemia associated with suppression of renin and Aldosterone and completely reversed by dietary sodium restriction
    322. Genetic variants in the epithelial sodium channel in relation to Aldosterone and potassium excretion and risk for hypertension
    323. Plasma renin activity and angiotensin I and Aldosterone concentrations in cats with hypertension associated with chronic renal disease.
    324. hypertension and primary hyperparathyroidism: the role of adrenergic and renin-angiotensin-Aldosterone systems.
    325. Myocardial ultrasonic backscatter in hypertension: relation to Aldosterone and endothelin
    326. Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, Aldosterone and blood pressure levels.
    327. Brain sodium channels and ouabainlike compounds mediate central Aldosterone-induced hypertension
    328. … of congestive heart failure: vasopressin, Aldosterone, and angiotensin II: further evidence for renal-adrenal interaction from studies in hypertension and in cirrhosis
    329. … -responsive Aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: adrenal hyperplasia) or low-renin essential hypertension.
    330. Investigation of the role of Aldosterone in hypertension associated with spontaneous pituitary‐dependent hyperadrenocorticism in dogs
    331. Ratio of serum Aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism
    332. Assessment of the novel selective Aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension
    333. Genetic polymorphism of the renin–angiotensin–Aldosterone system and arterial hypertension in the Italian population: the GENIPER Project
    334. Long-term safety and efficacy of the selective Aldosterone blocker eplerenone in patients with essential hypertension
    335. Haplotype analysis of Aldosterone synthase gene (CYP11B2) polymorphisms shows association with essential hypertension
    336. Can the genetic factors influence the treatment of systemic hypertension? The case of the renin-angiotensin-Aldosterone system
    337. Incidence of primary aldosteronism uncomplicated essential hypertension: a prospective study with elevated Aldosterone secretion and suppressed plasma renin …
    338. Non-genomic actions of Aldosterone: role in hypertension
    339. Aldosterone-producing adenoma without hypertension: a report of two cases
    340. The control of Aldosterone secretion in normal and hypertensive man: abnormal renin-Aldosterone patterns in low renin hypertension
    341. Relation of renin, angiotensin II, and experimental renal hypertension to Aldosterone secretion
    342. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension
    343. An abnormal sodium metabolism in Japanese patients with essential hypertension, judged by serum sodium distribution, renal function and the renin-Aldosterone …
    344. Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, Aldosterone-producing adenoma, and pheochromocytoma
    345. Age versus urinary sodium for judging renin, Aldosterone, and catecholamine levels: studies in normal subjects and patients with essential hypertension
    346. Systemic hypertension after cardiac transplantation: effect of cyclosporine on the renin-angiotensin-Aldosterone system
    347. Angiotensin, Aldosterone and human arterial hypertension
    348. Is Aldosterone the missing link in refractory hypertension?: Aldosterone-to-renin ratio as a marker of inappropriate Aldosterone activity
    349. Effect of chronic diuretic treatment on the plasma renin‐angiotensin‐Aldosterone system in essential hypertension.
    350. > VI. RENIN, Aldosterone, AND hypertension: The Intercurrent hypertension of Primary Aldosteronism
    351. Contrasting associations between Aldosterone synthase gene polymorphisms and essential hypertension in blacks and in whites
    352. Renin and Aldosterone levels and hypertension following envenomation in humans by the yellow scorpion Leiurus quinquestriatus
    353. Importance of the renin-angiotensin-Aldosterone system (RAS) in the physiology and pathology of hypertension
    354. Plasma Aldosterone response to ACTH in primary aldosteronism and in patients with low renin hypertension
    355. Plasma Aldosterone-renin interrelationships in various forms of essential hypertension: studies using a rapid assay of plasma Aldosterone
    356. Production of experimental hypertension by Aldosterone
    357. hypertension and hypersalimentation. 1. Aldosterone hypertension.
    358. Renin, Aldosterone, body fluid volumes, and the baroreceptor reflex in the development and reversal of Goldblatt hypertension in conscious dogs
    359. Familial hyperpotassemia and hypertension accompanied by normal plasma Aldosterone levels: possible hereditary cell membrane defect
    360. Renin-angiotensin-Aldosterone system gene polymorphisms and hypertension in Hong Kong Chinese
    361. Abnormally sustained Aldosterone secretion during salt loading in patients with various forms of benign hypertension; relation to plasma renin activity
    362. Essential hypertension and Aldosterone
    363. … of Aldosterone in man: Evidence for regulation of electrolyte balance and arterial pressure by a renal-adrenal system which may be involved in malignant hypertension
    364. Serum Aldosterone level in patients with hypertension during treatment by acupuncture
    365. VI. RENIN, Aldosterone, AND hypertension: The Relationship Between Plasma Renin and Aldosterone in Normal Man
    366. Aldosterone metabolites and possible Aldosterone precursors in hypertension
    367. Aldosterone synthase (CYP11B2)− 344 C/T polymorphism is associated with left ventricular structure in human arterial hypertension
    368. Influence of plasma Aldosterone on left ventricular geometry and diastolic function in treated essential hypertension
    369. Effect of fructose-induced hypertension on the renin-angiotensin-Aldosterone system and atrial natriuretic factor
    370. Further studies on urinary Aldosterone in human arterial hypertension.
    371. The cardiac structure-function relationship and the renin-angiotensin-Aldosterone system in hypertension and heart failure
    372. Impact of renin-angiotensin-Aldosterone system gene variants on the severity of hypertension in patients with newly diagnosed hypertension
    373. Effect of thiazide diuretics on plasma volume, body electrolytes, and excretion of Aldosterone in hypertension
    374. Familial hyperkalemia, hypertension, and hyporeninemia with normal Aldosterone levels: A tubular defect in potassium handling
    375. Effects of amlodipine on urinary sodium excretion, renin-angiotensin-Aldosterone system, atrial natriuretic peptide and blood pressure in essential hypertension.
    376. Eplerenone: a selective Aldosterone receptor antagonist for hypertension and heart failure.
    377. Disparate patterns of Aldosterone response during diuretic treatment of hypertension
    378. Effect of atrial natriuretic factor on blood pressure, renin, and Aldosterone in Goldblatt hypertension.
    379. Results of adrenal surgery in patients with hypertension, Aldosterone excess, and low plasma renin concentration.
    380. Alterations in Aldosterone secretion and metabolism in low renin hypertension
    381. Regulation of cardiac output during Aldosterone-induced hypertension.
    382. Renin-Aldosterone profiling in hypertension
    383. Aldosterone studies in obese patients with hypertension
    384. Left ventricular hypertrophy in asymptomatic essential hypertension: its relationship with Aldosterone and the increase in sodium-proton exchanger activity.
    385. Reversal of cardiovascular structural changes when treating essential hypertension: the importance of the renin-angiotensin-Aldosterone system
    386. Combining renin-angiotensin-Aldosterone system blockade with diuretic therapy for treatment of hypertension
    387. Functional derangements in the regulation of Aldosterone secretion in hypertension.
    388. Role of renin-angiotensin-Aldosterone system in salt-sensitive hypertension induced by sensory denervation
    389. Endothelin receptor blockade lowers plasma Aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension
    390. Aldosterone and specific Aldosterone receptor antagonists in hypertension and cardiovascular disease
    391. Possible mechanism of action for Aldosterone-induced hypertension
    392. Aldosterone antagonists in the treatment of hypertension and target organ damage
    393. Effect of nifedipine on plasma renin, Aldosterone and catecholamines in arterial hypertension
    394. Enhanced Aldosterone response to angiotensin II in human hypertension.
    395. Aldosterone and renin in essential hypertension.
    396. Role of the Aldosterone system in the salt-sensitivity of patients with benign essential hypertension
    397. Symptoms and the distress they cause: comparison of an Aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension
    398. Renin-angiotensin-Aldosterone and hypertension
    399. Electrolyte metabolism and Aldosterone secretion in benign and malignant hypertension
    400. Alterations of calcium, magnesium, and zinc in essential hypertension: their relation to the renin-angiotensin-Aldosterone system
    401. Aldosterone excretion in essential hypertension
    402. Calcium metabolism and the renin-Aldosterone system in essential hypertension.
    403. Does the renin-angiotensin-Aldosterone system modify cardiac structure and function in essential hypertension?
    404. The steroid content of adrenal adenomas and measurements of Aldosterone production in patients with essential hypertension and primary aldosteronism
    405. The role of Aldosterone in the development of hypertension in spontaneously hypertensive rats
    406. Malignant hypertension due to an Aldosterone producing adrenal adenoma
    407. Effect of corticotropin on Aldosterone excretion and plasma renin in normal subjects, in essential hypertension and in primary aldosteronism
    408. Role of renin and Aldosterone in hypertension due to a renin-secreting tumor
    409. Studies on Aldosterone: II. hypertension as a cumulative effect of Aldosterone administration
    410. Unexpected pressor responses to propranolol in essential hypertension: an interaction between renin, Aldosterone and sympathetic activity
    411. Low-renin, low-Aldosterone hypertension and abnormal cortisol metabolism in a 19-month-old child
    412. The role of the renin-angiotensin-Aldosterone system in circulatory control and hypertension.
    413. Regression of left ventricular hypertrophy in patients with hypertension: blockade of the renin-angiotensin-Aldosterone system
    414. Influence of sodium intake on hydrochlorothiazide‐induced changes in blood pressure, serum electrolytes, renin and Aldosterone in essential hypertension
    415. Malignant hypertension: effect of therapy on renin and Aldosterone
    416. Role of Aldosterone in angiotensin II-induced hypertension in rats
    417. Effects of losartan on the renin-angiotensin-Aldosterone axis in essential hypertension.
    418. The influence of a heparin-like compound on hypertension, electrolytes and Aldosterone in man
    419. hypertension with Aldosterone excess and low plasma-renin: preoperative distinction between patients with and without adrenocortical tumour
    420. Renin-angiotensin-Aldosterone system and G-protein beta-3 subunit gene polymorphisms in salt-sensitive essential hypertension
    421. Aldosterone diagnosis in hypertension: comparative evaluation of radioimmunoassays for urinary Aldosterone and 18-OH-corticosterone
    422. Renin–Angiotensin–Aldosterone System Loci and Multilocus Interactions in Young‐Onset Essential hypertension
    423. Effects of glucocorticoid administration on Aldosterone excretion and plasma renin in normal subjects, in essential hypertension and in primary aldosteronism
    424. hypertension corrected and Aldosterone responsiveness to renin-angiotensin restored by long-term dexamethasone in glucocorticoid-suppressible …
    425. Serum Aldosterone changes during hyperinsulinemia are correlated to body mass index and insulin sensitivity in patients with essential hypertension
    426. Renin, Aldosterone, sodium and hypertension
    427. Molecular variants in the P450c11AS gene as determinants of Aldosterone synthase activity in the Dahl rat model of hypertension
    428. Gene polymorphisms of the renin-angiotensin-Aldosterone system and essential arterial hypertension in childhood.
    429. Abnormal responsiveness of the renin Aldosterone system to acute stimulation in patients with essential hypertension
    430. hypertension induced by oral contraceptives containing estrogen and gestagen: effects on plasma renin activity and Aldosterone excretion
    431. Aldosterone secretion in hypertension
    432. Effects of biobehaviorally-assisted relaxation training on blood pressure, plasma renin, cortisol, and Aldosterone levels in borderline essential hypertension.
    433. Renin-angiotensin-Aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in …
    434. A decreased metabolic clearance rate of Aldosterone in benign essential hypertension
    435. Plasma renin activity and plasma Aldosterone concentrations in untreated Nigerians with essential hypertension.
    436. Adrenal sensitivity to angiotensin II and undiscovered Aldosterone stimulating factors in hypertension
    437. Renin-angiotensin-Aldosterone system and sodium balance in experimental renal hypertension
    438. Interaction between Aldosterone secretion, sodium and potassium balance, and angiotensin activity in man: studies in hypertension and cirrhosis
    439. Coronary microvascular fluid flux and permeability: influence of angiotensin II, Aldosterone, and acute arterial hypertension
    440. Sodium sensitivity in essential hypertension: role of the renin-angiotensin-Aldosterone system and predictive value of an intravenous frusemide test.
    441. Altered renin-angiotensin-Aldosterone relationships in normal renin essential hypertension.
    442. Maternal hypertension and progeny blood pressure: role of Aldosterone and 11β-HSD
    443. Dysregulation of Aldosterone secretion and its relationship to the pathogenesis of essential hypertension
    444. Artificial mutations in P450c11AS (Aldosterone synthase) can increase enzymatic activity: a model for low-renin hypertension?
    445. Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium, and the renin-Aldosterone system
    446. Systemic systolic hypertension in the elderly: correlation of hemodynamics, plasma volume, renin, Aldosterone, urinary metanephrines and response to thiazide …
    447. Renin-angiotensin-Aldosterone system during chronic thiazide therapy of benign hypertension
    448. Angiotensin and Aldosterone in renovascular hypertension
    449. Studies of the renin-angiotensin-Aldosterone system in patients with hypertension and in normal subjects
    450. Metabolic cardiovascular risk factors and the renin-Aldosterone system in essential hypertension.
    451. Acromegaly and hypertension: prevalence and relationship to the renin-angiotensin-Aldosterone system
    452. Effects of angiotensin infusions on Aldosterone and electrolyte excretion in normal subjects and patients with hypertension and adrenocortical disorders
    453. Response of Aldosterone and 18-hydroxycorticosterone to angiotensin II in normal subjects and patients with essential hypertension, Conn’s syndrome, and …
    454. Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in Aldosterone-induced hypertension
    455. Calcium sensitivity of isometric force in intact and chemically skinned aortas during the development of Aldosterone-salt hypertension in the rat.
    456. Effect of posture on the plasma concentrations of Aldosterone in hypertension and primary hyperaldosteronism
    457. Altered Aldosterone response to salt intake and angiotensin II infusion in young normotensive men with parental history of arterial hypertension
    458. Aldosterone receptor antagonists for hypertension
    459. … of angiotensin converting enzyme inhibitors in essential and renal hypertension: effects of captopril and enalapril on renin-angiotensin-Aldosterone, renal function and …
    460. The role of ACTH in the episodic release of Aldosterone in patients with idiopathic adrenal hyperplasia, hypertension, and hyperaldosteronism
    461. Low renin,“normal” Aldosterone and hypertension: Circadian rhythm of renin, Aldosterone, Cortisol and growth hormone
    462. Vascular responsiveness in rats resistant to Aldosterone-salt hypertension.
    463. hypertension with Aldosterone excess.
    464. Acute effects of the calcium antagonist, nifedipine, on blood pressure, pulse rate, and the renin-angiotensin-Aldosterone system in patients with essential hypertension
    465. The promise of selective Aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure
    466. Long-term effects of irbesartan and atenolol on the renin-angiotensin-Aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular …
    467. hypertension caused by an Aldosterone-secreting adenoma: occurrence in a 7-year-old child
    468. A delayed suppression of the renin-Aldosterone axis following saline infusion in human hypertension.
    469. The effect of low and high sodium diets on plasma atrial natriuretic factor, the renin‐Aldosterone system and blood pressure in subjects with essential hypertension
    470. Renin-angiotensin-Aldosterone system in pregnancy-induced hypertension
    471. Effect of angiotensin converting enzyme inhibition on blood pressure, plasma renin activity and plasma Aldosterone in essential hypertension
    472. Plasma renin activity (PRA) and Aldosterone (PA) in patients with chronic glomerulonephritis (GN) and hypertension.
    473. The renin—angiotensin—Aldosterone system and carotid artery disease in mild-to-moderate primary hypertension
    474. Renin-angiotensin-Aldosterone system, RR interval, and blood pressure variability during postural changes in borderline arterial hypertension
    475. Adenovirus-mediated human prostasin gene delivery is linked to increased Aldosterone production and hypertension in rats
    476. Aldosterone and corticosterone secretion rates in rats with experimental renal hypertension
    477. Aldosterone in sustained essential hypertension
    478. Rhythm characteristics of plasma renin, Aldosterone and cortisol in five subtypes of mesor-hypertension
    479. Triamterene-Induced Changes in Aldosterone and Renin Values in Essential hypertension: Evidence of a Role for Aldosterone in Preventing Blood Pressure …
    480. Renin and Aldosterone in essential hypertension
    481. Aldosterone and electrolyte balance in human hypertension
    482. Quadric analysis in the preoperative distinction between patients with and without adrenocortical tumors in hypertension with Aldosterone excess and low plasma …
    483. Body fluid volumes and the response of renin and Aldosterone to short‐and long‐term thiazide therapy of essential hypertension
    484. Aldosterone, the adrenal cortex, and hypertension
    485. hypertension and Aldosterone overproduction without renin suppression in Cushing’s syndrome from an adrenal adenoma
    486. Circadian changes in plasma renin activity and plasma Aldosterone concentration in two-kidney hypertension rats.
    487. Aldosterone-related genetic effects in hypertension
    488. Heritable abnormalities of the renin-angiotensin-Aldosterone system in essential hypertension.
    489. … hypertension with penbutolol (Hoe 893d). I. Effects on blood pressure, pulse rate, catecholamines in blood and urine, plasma renin activity and urinary Aldosterone …
    490. Regulation of Aldosterone receptors in hypertension
    491. Plasma Renin Activity and in vitro Synthesis of Aldosterone by the Adrenal Glands of Rats with Spontaneous, Renal, or Pinealectomy‐Induced hypertension
    492. Use of the converting enzyme inhibitor enalapril in renovascular hypertension. Effect on blood pressure, renal function, and the renin-angiotensin-Aldosterone system.
    493. Influence of Aldosterone vs endothelin receptor antagonism on renovascular function in liquorice‐induced hypertension
    494. Controlled study of circadian rhythm of blood pressure in patients with Aldosterone-producing adenoma compared with those with essential hypertension
    495. Different regulation of cardiac and renal corticosteroid receptors in Aldosterone-salt treated rats: effect of hypertension and glucocorticoids
    496. The Aldosterone to renin ratio in secondary hypertension
    497. Plasma deoxycorticosterone and Aldosterone in essential hypertension
    498. Urinary Aldosterone and hypertension
    499. Changes in the renin-angiotensin-Aldosterone system and in sodium and potassium balance during development of renal hypertension in rats
    500. Experimental Aldosterone hypertension in the rat
    501. The renin-angiotensin-Aldosterone system: focus on its distinct role in arterial hypertension and its various inhibitors as a therapeutic strategy to effectively lower blood …
    502. Activity of renin-angiotensin-Aldosterone system (RAAS) and vasopressin level in patients with primary pulmonary hypertension
    503. … evidence on blocking the renin–angiotensin–Aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent …
    504. Aldosterone metabolic clearance is normal in low-renin essential hypertension
    505. Role of Aldosterone in the pathogenesis of hypertension
    506. Development of hypertension in rats treated with Aldosterone acetate
    507. Blunted Aldosterone responsiveness to angiotensin II in normotensive subjects with familial predisposition to essential hypertension.
    508. Relation between plasma renin activity, angiotensin, and Aldosterone and blood pressure in mild untreated hypertension.
    509. In vivo left ventricular function and collagen expression in Aldosterone/salt-induced hypertension
    510. Effects of long-term enalapril and losartan therapy of hypertension on cardiovascular Aldosterone
    511. Unilateral Page kidney hypertension in man: Studies of the renin-angiotensin-Aldosterone system before and after nephrectomy
    512. Captopril in hypertension with renal artery stenosis and in intractable hypertension; acute and chronic changes in circulating concentrations of renin, angiotensins I …
    513. … and calcium channel-blocking drugs on plasma Aldosterone responses to infusion of angiotensin II in normal subjects and patients with essential hypertension
    514. hypertension and hypokalemic alkalosis associated with underproduction of Aldosterone
    515. Perspectives on the renin-angiotensin-Aldosterone system in hypertension
    516. Aldosterone suppression with dopamine infusion in low-renin hypertension.
    517. Dissociation of plasma renin activity and Aldosterone in essential hypertension
    518. The relationship of Aldosterone synthase gene polymorphism with hypertension and left ventricular hypertrophy
    519. Plasma immunoreactive gamma melanotropin in patients with idiopathic hyperaldosteronism, Aldosterone-producing adenomas, and essential hypertension.
    520. Modifications of myocardial Na+,K+-ATPase isoforms and Na+/Ca2+ exchanger in Aldosterone/salt-induced hypertension in guinea pigs
    521. Nomograms relating Aldosterone excretion to urinary sodium and potassium in the pediatric population: Their application to the study of childhood hypertension
    522. Characteristics of adrenal-regeneration and Aldosterone hypertension.
    523. Renin–angiotensin–Aldosterone system polymorphisms and essential hypertension: where are we?
    524. Failure of chronic Aldosterone infusion to increase arterial pressure in dogs with angiotensin-induced hypertension.
    525. Renin-angiotensin-Aldosterone system in experimental renal hypertension in the rabbit
    526. Relationship of plasma renin activity and Aldosterone levels with hemodynamic functions in essential hypertension
    527. The renin-Aldosterone system in pre-eclampsia, essential and transient hypertension during pregnancy, and normotensive pregnant and non-pregnant control …
    528. Acute effects of captopril on cardiopulmonary hemodynamics and renin-angiotensin-Aldosterone and bradykinin profile in hypertension
    529. A study of urinary and intracellular sodium and potassium, renin, Aldosterone, and hypertension in blacks and Indians in Natal
    530. Dynamic Aldosterone and 18-hydroxydeoxycorticosterone studies in labile and stable benign essential hypertension
    531. Opposite associations of circulating Aldosterone and atrial natriuretic peptide with left ventricular diastolic function in essential hypertension
    532. Catecholamines and the renin-angiotensin-Aldosterone system during treatment with felodipine ER or hydrochlorothiazide in essential hypertension.
    533. Urinary Aldosterone and hypertension
    534. Effect of blood pressure angiotensin II and Aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with …
    535. The Role of Urinary PGE2 and Renin-Angiotensin-Aldosterone System in the Pathogenesis of Essential hypertension
    536. Dissociation in the excretion of different Aldosterone metabolites and unmetabolized (‘free’) Aldosterone in hypertension
    537. The Yucatan miniature swine: an improved pig model for the study of desoxycorticosterone-acetate (DOCA) and Aldosterone hypertension
    538. Relationship between plasma Aldosterone concentration and plasma potassium in patients with essential hypertension during alprenolol treatment
    539. hypertension with inappropriate Aldosterone stimulation: a syndrome
    540. The integrated concentration of plasma renin activity and Aldosterone in essential hypertension.
    541. Reduced Aldosterone metabolites in hypertension
    542. Relations between renin, Aldosterone and experimental hypertension in rats
    543. The gerontological decline of the renin-Aldosterone system: a chronobiological approach extended to essential hypertension
    544. Circulatory volume in essential hypertension. Relationships with age, blood pressure, exchangeable sodium, renin, Aldosterone and catecholamines.
    545. Abnormal urinary kallikrein in hypertension is not related to Aldosterone or plasma renin activity.
    546. Short‐term effects of atenolol and nifedipine on atrial natriuretic peptide, plasma renin activity, and plasma Aldosterone in patients with essential hypertension
    547. … Renin Activity Ratio in Hypertensive Patients with Increases of 11-Deoxycorticosterone and 18-Hydroxy-ll-Deoxycorticosterone: A Subtype of Essential hypertension?
    548. Renal function, body fluid volumes, renin, Aldosterone, and noradrenaline during treatment of hypertension with pindolol.
    549. The adrenal cortex and hypertension: some observations on a possible role for mineralocorticoids other than Aldosterone
    550. Suppression of plasma renin and Aldosterone in stress-salt hypertension in dogs
    551. Suppression of the Renin—Aldosterone System in Mild Essential hypertension
    552. Response of plasma Aldosterone to fludrocortisone in primary hyperaldosteronism and other forms of hypertension
    553. Dopaminergic regulation of circadian rhythms of blood pressure, renin and Aldosterone in essential hypertension
    554. The prevalence of hypertension in an unselected population, and the frequency of abnormalities of potassium, angiotensin II and Aldosterone in hypertensive subjects
    555. Antihypertensive and Aldosterone-lowering effects of synthetic atrial natriuretic factor in renin-dependent renovascular hypertension.
    556. The Renin‐Aldosterone System and Renal Hemodynamics in Patients with Posttransplant hypertension
    557. Aldosterone acts on the kidney, not the brain, to cause mineralocorticoid hypertension in sheep
    558. High-renin malignant hypertension secondary to an Aldosterone-producing adenoma
    559. Sodium balance, plasma renin, and Aldosterone in hypertension.
    560. Effects of enalapril maleate on blood pressure, renin-angiotensin-Aldosterone system, and peripheral sympathetic activity in essential hypertension.
    561. Aldosterone and magnesium in essential arterial hypertension.
    562. The effects of sodium loading and deprivation on plasma renin and plasma and urinary Aldosterone in hypertension
    563. hypertension due to coexisting pheochromocytoma and Aldosterone-producing adrenal cortical adenoma
    564. The renin-angiotensin-Aldosterone system and hypertension in primary hyperparathyroidism
    565. Altered Ca-dependent fluxes of 42K in rat aorta during Aldosterone-salt hypertension.
    566. Effects of ACTH and posture on Aldosterone metabolism in essential hypertension
    567. … and indirect measurement of urinary kallikrein excretion in patients with essential hypertension and normotensives: relation to age and plasma renin and Aldosterone …
    568. Aldosterone secretion by dogs during the developmental phase of Goldblatt hypertension
    569. Effect of chlorothiazide upon Aldosterone excretion and sodium and potassium balance in essential hypertension
    570. Effect of verapamil on renal plasma flow, glomerular filtration rate and plasma angiotensin II, Aldosterone and arginine vasopressin in essential hypertension
    571. Aldosterone in primary hypertension relationship to plasma renin activity and urinary electrolytes and a comparison with normotensive subjects
    572. The renin-Aldosterone system and thiazide-induced depletion of total body potassium in essential hypertension
    573. … enzyme inhibition on blood pressure, plasma renin activity (PRA) and plasma Aldosterone in hypertensive diabetics compared to patients with essential hypertension.
    574. The renin-Aldosterone system in exaggerated natriuresis of essential hypertension
    575. Role of Aldosterone in the antihypertensive effect of spironolactone in essential hypertension
    576. Central and renal circulation, renin and Aldosterone in plasma during prazosin treatment in essential hypertension
    577. Plasma Aldosterone in essential hypertension with low renin activity
    578. … of nicardipine, a calcium‐entry blocker: Effects on renal function, plasma renin activity, and Aldosterone concentration in mild‐to‐moderate essential hypertension
    579. The effect of indomethacin on plasma renin activity and urinary Aldosterone of patients with essential hypertension
    580. Effect of an Aldosterone antagonist on electrolytes and juxtaglomerular granularity in adrenal regeneration hypertension
    581. Candesartan cilexetil in hypertension: Effects of six weeks’ treatment on haemodynamics, baroreceptor sensitivity and the renin-angiotensin-Aldosterone system
    582. The metabolic clearance of Aldosterone decreases similarly during infusion of angiotensin II in patients with essential hypertension and in normal subjects
    583. Malignant hypertension and Aldosterone secretion: Influence of reversal and progression of the syndrome in two cases
    584. Prostanoids and Aldosterone-induced mild experimental hypertension in rats.
    585. … paper: the renin-angiotensin-Aldosterone system for blood pressure regulation and for subdividing patients to reveal and analyze different forms of hypertension
    586. Differences in adrenal cholesterol, ascorbic acid, circulating corticosterone and Aldosterone during the onset of hypertension in SHR vs WKy rats
    587. Responses of plasma catecholamines, renin-angiotensin-Aldosterone system, and atrial natriuretic peptide to exercise in patients with essential hypertension
    588. Efficacy of nicardipine slow release (SR) on hypertension, potassium balance and plasma Aldosterone in idiopathic aldosteronism.
    589. … beta adrenergic blockade with orally administered labetalol in hypertension: Studies on blood volume, plasma renin and Aldosterone and catecholamine excretion
    590. Effects of the selective mineralocorticoid receptor antagonist, eplerenone, in a model of Aldosterone-induced hypertension and cardiac fibrosis
    591. Renin, angiotensin II, Aldosterone, catecholamines, prostaglandins and vasopressin. The importance of pressor and depressor factors for hypertension in pregnancy
    592. The characterization of low renin hypertension by plasma renin activity and plasma Aldosterone concentration
    593. Plasma Aldosterone Response to Angiotensin II in Sodium‐Restricted Elderly Subjects with Essential hypertension
    594. Left ventricular hypertrophy and remodelling of resistance arteries: the role of activation of the renin–angiotensin–Aldosterone system in hypertension
    595. Blood volume and Aldosterone secretion in hypertension and primary aldosteronism.
    596. Solitary kidney and ageing as causes of low renin and Aldosterone concentrations: relevance to ‘low-renin’essential hypertension
    597. Effect of indapamide on the renin‐Aldosterone system, and urinary excretion of potassium and calcium in essential hypertension.
    598. Renin-Aldosterone system suppression during water immersion in renovascular hypertension.
    599. Relationships between sodium clearance, plasma renin activity, plasma Aldosterone, renal hemodynamics and blood pressure in essential hypertension
    600. An association between mineral metabolism and the renin-Aldosterone system in human hypertension.
    601. Dexamethasone-responsive hypertension in young women with suppressed renin and Aldosterone
    602. Abnormal vasopressin and Aldosterone response to furosemide in essential hypertension
    603. Effects of intravenous labetalol on blood pressure, angiotensin II and Aldosterone in hypertension: comparison with propranolol
    604. Circadian rhythm of renin and Aldosterone in unilateral renovascular hypertension: pre-and post-operative studies
    605. … between plasma Aldosterone and angiotensin II before and after noradrenergic inhibition in normal subjects and patients with mild essential hypertension
    606. Factors for postoperative persistent hypertension in patients with Aldosterone-producing adenoma
    607. Effects of experimental renal hypertension on Aldosterone biosynthesis by rat adrenal tissue
    608. Biochemical correction in the syndrome of hypertension and hyperkalaemia by severe dietary salt restriction suggests renin‐Aldosterone suppression critical in …
    609. Abnormal norepinephrine and Aldosterone responses to upright posture in nonmodulating hypertension
    610. … plasma renin activity and plasma Aldosterone concentration to long-term administration of captopril in patients with severe, treatment-resistant malignant hypertension
    611. Aldosterone-Induced hypertension: Effects of a Kininase Inhibitor
    612. Mechanism of inhibition of Aldosterone secretion by a Ca2+ channel blocker in patients with essential hypertension and patients with primary aldosteronism
    613. hypertension and mineralocorticoids. Usefulness of renin and Aldosterone measurements
    614. Hypotensive and natriuretic effects of nifedipine in essential hypertension. Role of renal kallikrein-kinin-prostaglandin and renin-angiotensin-Aldosterone systems.
    615. Captopril, Aldosterone and urinary kallikrein in primary hypertension
    616. Age-and sex-related differences in plasma Aldosterone in essential hypertension. Relationship to plasma renin activity
    617. The Renin-Angiotensin-Aldosterone System in hypertension.
    618. STRUCTURE‐FUNCTION RELATIONSHIPS OF Aldosterone SYNTHASE AND 11β‐HYDROXYLASE ENZYMES: IMPLICATIONS FOR HUMAN hypertension
    619. Effect of enalapril on renin, angiotensin converting enzyme activity, Aldosterone and prostaglandins in patients with hypertension.
    620. Aldosterone antagonism and hypertension
    621. The substitutive role of ACTH in supporting Aldosterone response to head-up tilt during acute renin suppression in patients with essential hypertension.
    622. Effect of a new mineralocorticoid antagonist mespirenone on Aldosterone-induced hypertension
    623. Functional aspects of the renin–angiotensin–Aldosterone system and angiotensin II receptor AT1 blockers in arterial hypertension
    624. Essential arterial hypertension: plasma and urinary Aldosterone alterations.
    625. Aldosterone responsiveness to angiotensin II after sodium restriction in subjects with low renin essential hypertension
    626. Renin-angiotension-Aldosterone system, urinary prostaglandins and kallikrein in pregnancy-induced hypertension: evidence for a dysregulation of the renin …
    627. Effects of felodipine on natriuresis, atrial natriuretic factor, the renin-angiotensin-Aldosterone system, and blood pressure in essential hypertension.
    628. Aldosterone response to prolonged ACTH infusion in juvenile hypertension
    629. Adrenal Cortex, Aldosterone, and hypertension: Report of an International Workshop
    630. The role of Aldosterone in the response to treatment of primary hypertension
    631. Metabolism of Aldosterone in dogs with renovascular hypertension
    632. Renin-angiotensin-Aldosterone system in arterial hypertension.
    633. Effect of propranolol therapy on Aldosterone responses to angiotensin II and adrenocorticotropic hormone in essential hypertension
    634. Renin-angiotensin and Aldosterone in Experimental hypertension
    635. Effects of the Calcium Antagonist Felodipine on the Sympathetic and Renin‐Angiotensin‐Aldosterone Systems in Essential hypertension
    636. Primary aldosteronism due to Aldosterone producing adenoma without hypertension
    637. The Acute and Chronic Effects of Betaxolol on Blood Pressure, Renin‐Aldosterone, and Renal Function in Essential hypertension
    638. Renin-hyporesponsiveness in essential hypertension dissociation between plasma renin and catecholamines or Aldosterone following furosemide
    639. Effects of nisoldipine on sympathetic activity, the renin-angiotensin-Aldosterone system, and water-sodium-calcium metabolism in patients with essential hypertension.
    640. Effect of angiotensin converting-enzyme inhibition on potassium-mediated Aldosterone secretion in essential hypertension
    641. … haemodynamics and the renin-angiotensin-Aldosterone system in normotensive subjects with a familial predisposition to hypertension: changes during increased salt …
    642. CAPTOPRIL IN PRIMARY hypertension: Effects related to the renin‐angiotensin‐Aldosterone and kallikrein‐kinin systems.
    643. … reduces Aldosterone and 18-hydroxycorticosterone response to angiotensin II in patients with essential low-renin hypertension and idiopathic hyperaldosteronism
    644. Perinephritis hypertension in Macaca fascicularis (cynomolgus monkey): studies of the renin-angiotensin-Aldosterone axis and renal hemodynamic function.
    645. … -angiotensin-Aldosterone, and cardiovascular response during exercise following acute and long-term calcium antagonism with felodipine in essential hypertension.
    646. Urinary excretion of renal prostaglandins, kallikrein, vasopressin and Aldosterone in essential hypertension
    647. Severe hypertension in a ten-year-old boy secondary to an Aldosterone-producing tumour identified by adrenal sonography.
    648. Aldosterone: clinical implications in essential hypertension
    649. Role of Aldosterone in the initial stage of two forms of experimental vasorenal hypertension
    650. The renin-angiotensin-Aldosterone system and arterial hypertension in patients with rheumatoid arthritis
    651. … for” Aldosterone” and” 18-hydroxycorticosterone” in unprocessed urine, and their use in screening to distinguish primary aldosteronism from hypertension.
    652. hypertension, angiotensin II, Aldosterone, and race
    653. Jejunal permeability to water and electrolytes in patients with chronic intrahepatic hypertension: evidence for a role of Aldosterone.
    654. <